This article was originally published in The Rose Sheet
In a Q&A posted to FDA’s website, new CFSAN Director Susan Mayne says she’s “trying to learn, as rapidly as I can, everything I can about the safety of foods and cosmetics.” More news in brief.
You may also be interested in...
CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.